SCHEMBL7106557

SCHEMBL7106557

OC[C@@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)c1cnc2ccccc2n1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CD209 Q9NNX6 3/20 0.44
SYNJ2 O15056 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ABL1 P00519 1/20 0.39
ALPL P05186 1/20 0.39
POLB P06746 1/20 0.39
ALPI P09923 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
ALPG P10696 1/20 0.39
PABPC1 P11940 1/20 0.39
RECQL P46063 1/20 0.39
GALK1 P51570 1/20 0.39
CASP7 P55210 1/20 0.39
CASP6 P55212 1/20 0.39
MCL1 Q07820 1/20 0.39
RIN1 Q13671 1/20 0.39
EIF4H Q15056 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7106637 1.00 CD209 (0.44) CD209SYNJ2KDM4EABL1ALPL
SCHEMBL7105467 0.82 CD209 (0.42) CD209
SCHEMBL7103572 0.82 CD209 (0.42) CD209
SCHEMBL22589721 0.77 SYNJ2 (0.40) CD209SYNJ2KDM4EABL1ALPL
SCHEMBL24292439 0.74 CD209 (0.45) CD209SYNJ2KDM4EABL1ALPL
SCHEMBL30480663 0.74 CD209 (0.45) CD209SYNJ2KDM4EABL1ALPL
SCHEMBL22901584 0.74 CD209 (0.45) CD209SYNJ2KDM4EABL1ALPL
SCHEMBL14668758 0.74 CD209 (0.45) CD209SYNJ2KDM4EABL1ALPL
SCHEMBL17866989 0.74 CD209 (0.45) CD209SYNJ2KDM4EABL1ALPL
Maltitol SCHEMBL21947406 0.71 L3MBTL1 (0.41) CD209SYNJ2KDM4EABL1ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030207886-A1 Preparation containing quinoxaline derivatives MERCK PATENT GMBH (DE) 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207886-A1 Preparation containing quinoxaline derivatives CUTA, XPA, NQO2 CD209 4472/4885SYNJ2 1957/4885KDM4E 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.